Tasca Therapeutics Launches with $52 Million Series A Financing to Develop Small Molecule Inhibitors for Multiple Oncology Indications
Proceeds from the financing to be utilized to complete proof of concept Phase 1/2 clinical study for lead candidate, CP-383 Financing co-led by Regeneron Ventures and Cure Ventures with participation by Invus Group Praveen Tipirneni…